Kornimate/medical-research-clean huggingface dataset:
postoperative pain intensity after pulpotomy

Conditions: Symptomatic Irreversible Pulpitis

Summary: introduction: this study aimed to compare postoperative pain rates following sodium hypochlorite (naocl) and ktp laser-assisted pulpotomy treatments in permanent teeth with deep caries, and symptomatic irreversible pulpitis. methods: ninety patients complaining of permanent teeth pain due to symptomatic irreversible pulpitis were randomly divided into 3 equal groups. preoperative pain levels were recorded. after the initial bleeding control was achieved with saline, complete hemostasis was achieved by applying saline (control group), 2.5% naocl, or ktp laser according to randomly determined patient groups. patients were asked to mark their pain level on the visual pain scale at the 6th, 24th, 48th, and 72nd hours, and 7th and 30th days depending on the severity of the pain. the permanent restoration was completed after 7 days. results: according to the present study, the statistical difference between the groups in terms of preoperative pain and percussion pain levels was insignificant. there was no significant difference between the groups in terms of demographic data. the postoperative pain level of the ktp laser group was significantly lower at the 6th hour compared to the saline group. there was no significant difference between the groups in terms of postoperative pain level at other time intervals. the greatest pain scores occurred in all groups at 6th hour. conclusions: ktp laser can be preferred primarily in reducing postoperative pain in pulpotomy treatments. ktp laser or naocl assisted pulpotomy can be an effective treatment for pain reduction in permanent teeth with symptomatic irreversible pulpitis.


Eligibility criteria:
inclusion criteria: * the patient should be ≥ 18 years old, a single tooth in every patient * must be signs of irreversible pulpitis, such as persistent pain that begins spontaneously and/or is exacerbated by cold. this situation should be repeated with the cold test. * irreversible pulpitis diagnosed, with or without symptomatic apical periodontitis * no systemic disease * should give a positive response to electrical and thermal tests * must be the opposite tooth. * the tooth is restorable, probing pocket (3mm) depth, and mobility are within normal limits exclusion criteria: * presence of allergies * using analgesics in the last 12 hours or antibiotics in the last 1 week before the procedure. * presence of swelling, palpation pain or sinus tract before treatment, root fracture or crack. * failure to control bleeding within 6 minutes, * presence of bruxism or open apex. * insufficient bleeding after pulp exposure * observation of advanced canal calcification * presence of internal or external root resorption.

Keywords: irreversible pulpitis ktp laser mineral trioxide aggregate postoperative pain pulpotomy visual analog scale
effectiveness of an interactive consulting system to enhance patients' decision-making: a randomized controlled trial

Conditions: Age-related Cataract

Summary: to compare the effectiveness of an interactive mobile chatbot and traditional decision aid booklets to enhance informed decisions made by cataract patients. the chatbot was built based on large language models, and could generate chatgpt-level responses.

cataract surgery is the only way to treat age-related cataract. for patients at early or moderate stages, cataract surgery is an elective surgery without objective indications. therefore, patients are uaually not aware whether they should receive the surgery or not. in clinical practice, traditional patient decision aids (pda) booklets are used to provide health education to patients. however, pdas lack real-time interaction with patients, and are unable to answer the new questions raised. patients still have doubts about whether they should receive cataract surgery or not. in this study, the investigators aim to assess the effectiveness of an interactive q\&a mobile application based on natural language processing technology to enhance informed decisions made by cataract patients.

Eligibility criteria:
inclusion criteria 1. individuals aged 50-80, living in the designated research area for more than 6 months; 2. primary diagnosis of cataract and have not undergone cataract surgery; 3. ownership of a smartphone/tablet capable of using the study app and the ability to smoothly type in chat content 4. willing to participate in the research and provide informed content. exclusion criteria 1. blindness in both eyes (manifesting as a distant vision less than 3/60); 2. eye, hearing, or mental disorders that hinder reading or telephone interviews; 3. permanent vision loss due to eye diseases other than cataracts, which cannot be corrected by cataract surgery; 4. contraindications for cataract surgery.
a weight management intervention for overweight chinese cancer survivors

Conditions: Cancer; Weight Loss; Overweight and Obesity

Summary: this study aims to conduct a feasibility trial to examine the feasibility and acceptability of conducting a randomized controlled trial that evaluates the effect of the weight management intervention on anthropometric measures (body weight and bmi), dietary quality, physical activity levels, physical and psychosocial functioning, self- efficacy for weight loss and quality of life.

the primary aim of the proposed study is to assess the feasibility and acceptability of conducting a randomized controlled trial (rct) that evaluates an adaptive weight management intervention, tailored to chinese cancer survivors with overweight/obesity after the completion of cancer survivorship care, to improve anthropometric measures (body weight and bmi), dietary quality, physical activity levels, physical and psychosocial functioning, self-efficacy for weight loss and quality of life. according to the consolidation standards of reporting trials (consort) guidelines for reporting feasibility trials, hypothesis setting for a feasibility trial is not recommended, given that pilot trials are often underpowered to detect difference which instead should be the aim of the main trial.

Eligibility criteria:
inclusion criteria: * chinese cancer survivors attending the one-off face-to-face survivorship care clinic * who are cantonese- or mandarin- speaking * aged 18 or above * diagnosed with early-stage disease (stage 0-ii) * have completed primary and adjuvant treatments such as chemotherapy and radiotherapy * and with a bmi ≥ 23 kg/m2, as indicative as overweight or obesity using asia-pacific bmi cutoffs at 3-months reassessment exclusion criteria: * non-chinese survivors with advanced or metastatic disease * who have communication difficulties, mobility impairment or cognitive disabilities
risk factors for predictors of in-hospital death in acute fulminant myocarditis

Conditions: Viral Myocarditis; Cardio-Renal Syndrome; Risk Factor, Cardiovascular

Summary: the investigators performed a retrospective, single-center observational study, and the participants with acute fulminant myocarditis were included.then, the investigator analyzed the risk factors of in-hospital death in these participants with acute fulminant myocarditis.


Eligibility criteria:
inclusion criteria: clinical diagnosis of acute fulminant myocarditis exclusion criteria: chronic renal dysfunction refuse medical treatments
study of alxn2050 in adult participants with generalized myasthenia gravis

Conditions: Generalized Myasthenia Gravis; Myasthenia Gravis

Summary: this study will evaluate the efficacy and safety of alxn2050 (120 milligrams \[mg\], 180 mg) in participants with generalized myasthenia gravis (gmg). safety will be monitored throughout the study.

the study consists of a blinded 8-week primary evaluation period (pep) and a blinded 26-week extended treatment period (etp). after completion of 34 weeks of treatment, participants will enter an open-label extension (ole) period for up to 1.5 years.

Eligibility criteria:
inclusion criteria: * diagnosed with mg at least 3 months (90 days) prior to the date of the screening visit. confirmation of mg must be made via the following: 1. positive serologic test for anti achr antibodies at the screening visit, and 2. abnormal neuromuscular transmission demonstrated by single fiber electromyography or repetitive nerve stimulation, or 3. positive response to an achei test (eg, edrophonium chloride test), or 4. improvement of signs or symptoms related to mg during treatment with an oral achei, as determined by the treating physician * myasthenia gravis foundation of america clinical classification class ii to iv at the screening visit. * mg-adl total score must be ≥ 5 (with at least 50% of the score attributed to non-ocular elements) at the screening visit and at randomization (day 1). * participants receiving treatment with protocol-specified immunosuppressive therapies, corticosteroids, or acetylcholinesterase inhibitors must have been receiving treatment and on a stable dose prior to the date of the screening visit, with no changes to the regimen expected during screening, the pep, and/or the etp. exclusion criteria: * estimated glomerular filtration rate ≤ 30 milliliters/minute/1.73 squared meters during screening calculated by chronic kidney disease epidemiology collaboration. * history of thymectomy, thymomectomy, or any other thymic surgery within 12 months prior to the screening visit. * any untreated thymic malignancy, carcinoma, or thymoma. participants with a history of treated thymic malignancy or carcinoma are eligible for enrollment if they meet pre-specified conditions outlined in the protocol. * clinical features consistent with clinical deterioration at the time of the screening visit or at any time during the screening period prior to randomization (day 1). * use of the following within the time periods specified below: 1. intravenous immunoglobulin g or subcutaneous immunoglobulin within the 4 weeks (28 days) prior to the screening visit. 2. use of tacrolimus or cyclosporine within the 4 weeks (28 days) prior to the screening visit.

Keywords: alxn2050 gmg
effect of sevoflurane in postoperative troponin i levels in children undergoing congenital heart defects surgery

Conditions: Congenital Heart Defects

Summary: the main purpose of this study is to compare myocardial injury of patients undergoing congenital cardiac defects repair surgery (rachs risk score one, two or three) under total intravenous anesthesia compared to inhalation anesthesia with sevoflurane. the primary aim of the study is to evaluate the troponin i levels in patients following congenital heart surgery and elucidate if one of the two anesthetic techniques (tiva x inhalation anesthesia) is more effective in reducing troponin i levels in the first 72h after surgery.. sixty six are planned to be included in the study and the follow-up will take approximately 3 days for the primary outcome. as a secondary outcome evaluate the bnp, cpk and ckmb postoperative levels in the same period (72h), also icu and hospital lengh of stay (los), duration of mechanical ventilation, inotropic/vasoactive drugs use and incidence of renal injury (according to pediatric rifle score).


Eligibility criteria:
inclusion criteria * written informed consent (signed by the parents) * scheduled congenital heart defect repair surgery rachs risk score 1, 2 or 3. on-pump surgery * age: 2 years old (completed) or younger * patients without previous kidney disease or any contraindication for inhaled anesthesia (including previous unusual response to an anesthetic agent) * no previous general anesthesia in the last 30 days. exclusion criteria * emergency surgery * off-pump surgery (surgery plan changed by the surgeon after patient's randomization) * refuse to take part of the study or ask to leave the trial
study of veliparib in combination with nivolumab and platinum doublet chemotherapy in participants with metastatic or advanced non-small cell lung cancer (nsclc)

Conditions: Non-Small Cell Lung Cancer

Summary: this study seeks to establish the recommended phase 2 dose (rptd) of veliparib in combination with nivolumab and platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed) (phase 1 portion) and to assess whether the addition of nivolumab to veliparib in combination with platinum doublet chemotherapy results will improve progression free survival (pfs) compared to veliparib with platinum doublet chemotherapy alone in participants with metastatic or advanced non-small cell lung cancer (nsclc) (phase 2 portion). a strategy decision was made not to proceed to phase 2 portion of this study due to change in standard of care.


Eligibility criteria:
inclusion criteria: * participant must have a life expectancy greater than 12 weeks, * participant must have cytologically or histologically confirmed non-small cell lung cancer (nsclc). * participant must have metastatic or advanced nsclc (stage iiib or iv) that is not amenable to surgical resection or radiation or chemoradiation with curative intent at time of study screening. * participant must have at least 1 unidimensional measurable nsclc lesion on a computed tomography (ct) scan as defined by response evaluation criteria in solid tumors (recist) (version 1.1). * participant must have resolution to grade 1 or lower of any toxic effects (excepting alopecia) of the most recent therapy prior to cycle 1 day 2. * participant must have an eastern cooperative oncology group (ecog) performance score of 0 to 1. * participant must have adequate bone marrow, renal, and hepatic function. exclusion criteria: * participant has received prior cytotoxic chemotherapy (including chemotherapy in combination with radiotherapy) for nsclc, except for adjuvant or neoadjuvant therapy accompanied by surgery with curative intent that was completed one year prior to cycle 1 day -2. * participant has received prior therapy with a poly-(adp-ribose)-polymerase (parp) inhibitor. * participant has received prior treatment with any anti-programmed cell death protein-1 (anti-pd-1), or pd ligand-1 (pd-l1) or pd ligand-2 (pd-l2) agent or an antibody targeting other immunoregulatory receptors or mechanisms. * participant has received radiation therapy to lung greater than 30 gy within 6 months, or antineoplastic biologic therapy within 21 days, or major surgery within 21 days, or tyrosine kinase inhibitor therapy within 7 days, or palliative radiation within 7 days of the first dose of study medication. * participant has untreated central nervous system (cns) metastases.

Keywords: metastatic non-small cell lung cancer eastern cooperative oncology group (ecog) veliparib nivolumab platinum doublet chemotherapy carboplatin paclitaxel pemetrexed response evaluation criteria in solid tumors (recist) common terminology criteria for adverse events (ctcae) poly (adp) ribose polymerase (parp) immuno oncology metastatic or advanced non-small cell lung cancer (nsclc)
a study of dovitinib versus sorafenib in adult patients with hepatocellular carcinoma (hcc) as a first line treatment

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this open-label, randomized, phase ii study is to compare the safety and efficacy of dovitinib versus sorafenib as first-line treatment in adult patients with advanced hepatocellular carcinoma (hcc). this trial will be opened in countries of the asia-pacific region.


Eligibility criteria:
inclusion criteria: diagnosis of advanced hepatocellular carcinoma (hcc) according to the aasld guidelines * advance hcc stage b and c according to bclc staging classification * child pugh a * at least one measurable lesion as assessed by ct or mri * ecog ps of 0 or 1 * adequate bone marrow, liver, and renal function exclusion criteria: * prior systemic therapy for hcc * brain metastases * active bleeding (including variceal bleeding as the result of esophageal varices) patients who have received a liver transplant or are awaiting an immediate transplant other protocol-defined inclusion/exclusion criteria may apply

Keywords: hepatocellular carcinoma hcc liver cancer child pugh a hcc stage c
cd45ra depleted peripheral stem cell addback for viral or fungal infections post tcrαβ/cd19 depleted hsct

Conditions: Acute Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndromes; Acute Lymphoblastic Leukemia; Mixed Lineage Leukemia; Lymphoblastic Lymphoma; Burkitt Lymphoma; Juvenile Myelomonocytic Leukemia

Summary: the major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (hla) matched siblings are graft vs host disease (gvhd) and life threatening infections. t depletion of the donor hematopoietic stem cell graft is effective in preventing gvhd, but immune reconstitution is slow, increasing the risk of infections. an addback of donor cd45ra (naive t cells) depleted cells may improve immune reconstitution and help decrease the risk of infections.

the risk of severe graft versus host disease (gvhd) is increased with the use of unrelated and partially matched related donors. t cell depletion reduces the risk of severe gvhd, but immune reconstitution is delayed. important memory t cells that may protect patients from fungal and viral infections are also removed in the t depletion process. cd45ra depletion has been studied both as a single step to reduce the risk of gvhd, and also, in conjunction with αβtcr depleted hematopoietic stem cell grafts to accelerate immune reconstitution. this is a single institutional pilot trial of this t cell depletion technique. patients with acute leukemias at high risk for relapse are eligible to participate. patients will be given cd45ra depleted donor peripheral stem cells (pscs) following t depleted hematopoietic stem cell transplant (hsct). a short course of gvhd prophylaxis will be used after cd45ra depletion.

Eligibility criteria:
inclusion criteria: 1. age: patients \<25 years. 2. first allogeneic hsct only. 3. disease eligibility: acute leukemias at high risk for relapse including positive minimal residual disease at end consolidation, high risk cytogenetics, or relapse. hematologic malignancies including: acute myeloid leukemia, myelodysplastic syndromes, acute lymphoblastic leukemia, mixed lineage or bi-phenotypic leukemia, lymphoblastic or burkitts, juvenile myelomonocytic leukemia 4. evaluation of organ and infectious status as per our bone marrow transplant standard operating procedure (bmt sop). 5. signed consent by parent/guardian or able to give consent if \>18 years. exclusion criteria: 1. patients who do not meet institutional disease, organ or infectious criteria 2. no suitable donor available for mobilized peripheral stem cells 3. patients with genetic disorders including fanconi anemia, kostmann syndrome, dyskeratosis congenital or other dna repair defects. 4. patients with hodgkin lymphoma or non-burkitts, non-lymphoblastic lymphoma 5. pregnant participants donor selection and eligibility 1. unrelated donor meets national marrow donor program criteria for donation 2. hla testing/matching 3. donor must be willing to undergo granulocyte colony stimulating factor (gcsf) mobilization and peripheral blood stem cell collection
effect of oliceridine on rebound pain

Conditions: Rebound Pain; Arthroscopic Knee Surgery; Oliceridine

Summary: the purpose of this clinical study was to identify the risk factors for postoperative pain outburst in patients undergoing arthroscopic knee surgery after oliceridine and nerve block, and to evaluate the effect of oxeridine on early rehabilitation exercise in patients. a total of 320 patients undergoing arthroscopic knee arthroscopy under general anesthesia combined with femoral nerve block were selected to record the time and duration of postoperative pain outbreak, pain degree, age, gender, operation type, previous surgical history and other related risk factors.


Eligibility criteria:
inclusion criteria: 1. age 18-70 years old;2. body mass index (bmi) 18-30kg /m2;3. american society of anesthesiologists (asa) grade i to ii;4. hospital stay \>24h. exclusion criteria: 1. patients who cannot understand the numerical rating scale score and give feedback;2. known allergy to the drug in the study;3. infection of puncture site with nerve block;4. oral analgesics for more than 2 weeks before surgery;5. long-term use of glucocorticoids;6. simultaneous surgery on both limbs;7. a psychopath;8. severe compound trauma;9. pregnant and lactating women.
effect of puerarin on heart health in men

Conditions: Cardiovascular Disease Risk Factors

Summary: this study aims to assess the effect of puerarin supplementation on cardiovascular disease risk factors in men.

objectives: to assess the effect of puerarin supplementation on cardiovascular disease risk factors in men. study design: a randomized, double-blind, placebo-controlled, 2-way crossover trial of 12-week puerarin supplementation. study subjects: 234 hong kong chinese men aged 18-50 years without a history of cardiovascular disease. intervention: after assessing eligibility, all participants will be randomized to take a puerarin supplement in granules (90.2 mg daily) or a placebo, followed by a 4-week wash-out period, after which participants will be crossed over to the other intervention. primary outcomes: lipid profile (total cholesterol, low density lipoprotein (ldl) cholesterol, high density lipoprotein (hdl) cholesterol, triglycerides). secondary outcomes: cardiovascular disease risk factors, such as blood pressure and fasting glucose, as well as some potential mediating pathways, such as testosterone. methods: an intention to treat analysis will be used, assuming no changes in baseline value for missing follow up values. differences in outcomes between supplementation and placebo within participants will be compared using a paired t-test, after checking for the possibility of a carryover effect. expected results: the short-term effect of puerarin on cardiovascular disease risk factors in men will be obtained so as to confirm or refute previous trials usually with small sample sizes that suggest puerarin may improve lipid profile and reduce testosterone. the findings will also add evidence about the effects of puerarin on other potentially relevant risk factors, such as blood pressure, fasting glucose and testosterone, as well as some related biomarkers.

Eligibility criteria:
inclusion criteria: * men * aged 18 to 50 years * chinese ethnicity * willing to make return visits * not currently taking any traditional chinese medicine (including puerarin) supplementation * not currently receiving hormone replacement therapy, such as testosterone replacement therapy, in the past 12 months * free of any congenital diseases * free of any infectious diseases e.g. seasonal influenza * with no history of any chronic diseases including coronary heart disease (ischemic heart disease), myocardial infarction (heart attack), stroke, diabetes and cancer * have a 10-year risk of ischemic heart disease of less than 10% exclusion criteria: * women * men, who did not meet the aforementioned inclusion criteria, and/or unable or unwilling to provide consent

Keywords: puerarin lipids testosterone